Hanna Glenn J, Sridharan Vishwajith, Margalit Danielle N, La Follette Stephanie K, Chau Nicole G, Rabinowits Guilherme, Lorch Jochen H, Haddad Robert I, Tishler Roy B, Anderson Karen S, Schoenfeld Jonathan D
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.
HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications.
Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC.
We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay.
We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p= 0.03). When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p= 0.007).
Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.
人乳头瘤病毒（HPV）相关的口咽鳞状细胞癌（OPSCC）发病率正在上升。识别病毒介导疾病并预测OPSCC中HPV清除情况的实验室检测可能具有重要的预后意义。
在此，我们研究了局部晚期OPSCC患者在确定性放化疗（CRT）前后的血清、唾液HPV16早期（E）抗体。
我们前瞻性地检测了44例患者在CRT开始时及结束后6-7周的唾液、血清样本。通过可编程酶联免疫吸附测定法检测针对E2（NE2、CE2）、E6和E7的N端和C端片段的IgG抗体。
我们在HPV相关的OPSCC患者中观察到针对HPV相关E蛋白的血清抗体。大多数患者的唾液中检测到E7导向抗体，且与HPV状态相关（p = 0.03）。纵向分析时，治疗后唾液中E7抗体水平中位数显著下降（p = 0.007）。
我们的结果证明了在唾液和血清中检测HPV16 E抗体的可行性。特别是与其他E蛋白抗体相比，E7抗体在唾液中更易检测到。在不同时间点测量唾液中E7抗体水平可能有助于了解HPV清除情况，应对其预测复发风险的能力进行探索。
